Biogen will stop sales and development of its controversial Alzheimer’s drug Aduhelm, walking away from a drug that was approved against outside experts’ advice, led to congressional inquiries and faced pushback over its cost and efficacy.
The company didn’t take the official step of pulling the drug from the market, but instead handed it over to original owner Neurimmune. The move essentially discontinues Aduhelm in its current form, and Biogen took a one-time charge of $60 million in the fourth quarter.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.